Head-To-Head Comparison: Oramed Pharmaceuticals (NASDAQ:ORMP) versus Veru (NASDAQ:VERU)

Oramed Pharmaceuticals (NASDAQ:ORMP) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Profitability

This table compares Oramed Pharmaceuticals and Veru’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
Veru	N/A	-54.72%	-39.09%

Analyst Recommendations

This is a breakdown of current recommendations for Oramed Pharmaceuticals and Veru, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0	1	0	0	2.00
Veru	1	0	3	0	2.50

Veru has a consensus price target of $23.00, suggesting a potential upside of 443.74%. Given Veru’s stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Oramed Pharmaceuticals.

Institutional & Insider Ownership

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Oramed Pharmaceuticals and Veru”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	N/A	N/A	$64.05 million	$2.59	1.47
Veru	$16.89 million	4.02	-$22.73 million	($0.89)	-4.75

Oramed Pharmaceuticals has higher earnings, but lower revenue than Veru. Veru is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Oramed Pharmaceuticals has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Veru has a beta of -1.14, meaning that its stock price is 214% less volatile than the S&P 500.

Summary

Oramed Pharmaceuticals beats Veru on 7 of the 12 factors compared between the two stocks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

About Veru

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.